Cited by 396Cancer, Hypoxia, and MetabolismRenal cell carcinoma treatmentErythropoietin and Anemia Treatment

Up-regulation of hypoxia-inducible factors HIF-1α and HIF-2α under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function

Krieg, Marion, Haas, Richard, Brauch, Hiltrud, Acker, Till, Flamme, Ingo, Plate, Karl H·2000·Oncogene

Abstract

Hypoxia induces transcription of a range of physiologically important genes including erythropoietin and vascular endothelial growth factor. The transcriptional activation is mediated by the hypoxia-inducible factor-1 (HIF-1), a heterodimeric member of the basic helix-loop-helix PAS family, composed of alpha and beta subunits. HIF-1alpha shares 48 per cent identity with the recently identified HIF-2alpha protein that is also stimulated by hypoxia. In a previous study of hemangioblastomas, the most frequent manifestation of hereditary von Hippel-Lindau disease (VHL), we found elevated levels of vascular endothelial growth factor and HIF-2alpha mRNA in stromal cells of the tumors. Mutations of the VHL tumor suppressor gene are associated with a variety of tumors such as renal clear cell carcinomas (RCC). In this study, we analysed the expression of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in a range of VHL wildtype and VHL deficient RCC cell lines. In the presence of functional VHL protein, HIF-1alpha mRNA levels are elevated, whereas HIF-2alpha mRNA expression is increased only in cells lacking a functional VHL gene product. On the protein levels, however, in VHL deficient cell lines, both HIF-alpha subunits are constitutively expressed, whereas re-introduction of a functional VHL gene restores the instability of HIF-1alpha and HIF-2alpha proteins under normoxic conditions. Moreover, immunohistochemical analyses of RCCs and hemangioblastomas demonstrate up-regul…

Integrity signals

Registry

Crossref · 10.1038/sj.onc.1203938

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In ccRCC, VHL loss impairs degradation of HIF-α proteins, leading to HIF accumulation irrespective of oxygen levels.

    “In ccRCC, VHL loss impairs degradation of HIF-α proteins, leading to HIF accumulation irrespective of oxygen levels (Gnarra et al., 1994;Krieg et al., 2000).”

    From Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer (2016) · cites this paper as Krieg et al., 2000

The citation lists haven’t been fetched yet

References 37 · Cited by 396

Authors
Krieg, M., Haas, R., Brauch, H., Acker, T., Flamme, I., & Plate, K. H.
Affiliations
  • University of Freiburg (DE)
  • Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology (DE)
  • University of Cologne (DE)
Venue
Oncogene
Published
2000-11-16
Volume
19
Issue
48
Pages
5435-5443
ISSN
  • 0950-9232 (ISSN-L)
  • 1476-5594
OpenAlex
W1996715681
Cited by
396
References
37
Citations by year
2026: 9 · 2025: 13 · 2024: 21 · 2023: 9 · 2022: 19 · 2021: 9 · 2020: 15 · 2019: 12 · 2018: 10 · 2017: 14 · 2016: 9 · 2015: 18 · 2014: 11 · 2013: 23 · 2012: 16
FWCI
6.77
Type
journal article
Language
en
Open access
closed
Locations
  • Oncogene (publishedVersion)
  • PubMed (publishedVersion)
Funders
Deutsche Forschungsgemeinschaft
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Renal cell carcinoma treatment
  • Health Sciences › Medicine › Hematology › Erythropoietin and Anemia Treatment
Keywords
hypoxia-inducible factor-1α, HIF-2α, von Hippel-Lindau tumor suppressor gene, clear cell renal cell carcinoma, VHL deficiency, normoxic conditions, angiogenesis, erythropoiesis, vascular endothelial growth factor, hemangioblastoma, tumor suppressor function
MeSH terms
Endothelial PAS Domain-Containing Protein 1, Carcinoma, Renal Cell, Cerebellum, DNA-Binding Proteins, von Hippel-Lindau Disease, Humans, Immunohistochemistry, Kidney Neoplasms, Ligases, Lymphokines, Monosaccharide Transport Proteins, Mutation, Nuclear Proteins, Oxygen, Proteins, RNA, Messenger, Transcription Factors, Tumor Cells, Cultured, Trans-Activators, Up-Regulation, Polymerase Chain Reaction, Genes, Tumor Suppressor, Endothelial Growth Factors, Hemangioblastoma, Tumor Suppressor Proteins, Vascular Endothelial Growth Factors, Vascular Endothelial Growth Factor A, Ubiquitin-Protein Ligases, Glucose Transporter Type 1, Basic Helix-Loop-Helix Proteins, Hypoxia-Inducible Factor 1, Von Hippel-Lindau Tumor Suppressor Protein, Hypoxia-Inducible Factor 1, alpha Subunit

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review